ImmunityBio, Inc. (FRA:26CA)
Germany · Delayed Price · Currency is EUR 5.20
+0.29 (5.84%)
At close: Jan 30, 2026
ImmunityBio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 81.92 | 14.15 | - | - | 0.93 | 0.61 |
Other Revenue | 0.64 | 0.6 | 0.62 | 0.24 | - | - |
| 82.56 | 14.75 | 0.62 | 0.24 | 0.93 | 0.61 | |
Revenue Growth (YoY) | 1025.96% | 2270.58% | 159.17% | -74.30% | 54.38% | -72.52% |
Gross Profit | 82.18 | 14.75 | 0.62 | 0.24 | 0.93 | 0.61 |
Selling, General & Admin | 157.61 | 173.38 | 135.32 | 108.71 | 126.76 | 61.02 |
Research & Development | 185.32 | 185.55 | 226.67 | 242.2 | 191.6 | 140.26 |
Operating Expenses | 342.93 | 358.93 | 361.99 | 350.91 | 318.36 | 201.28 |
Operating Income | -260.75 | -344.18 | -361.36 | -350.67 | -317.42 | -200.67 |
Interest Expense | -122.91 | -154.33 | -129.2 | -63.52 | -14.85 | -9.07 |
Interest & Investment Income | 5.29 | 7.98 | 1.13 | - | - | 2.44 |
Earnings From Equity Investments | - | - | -7.55 | -12.11 | -0.8 | - |
Other Non Operating Income (Expenses) | 30.3 | 77.52 | -84.44 | 16.91 | 4.81 | 0.02 |
EBT Excluding Unusual Items | -348.06 | -413.01 | -581.41 | -409.38 | -328.27 | -207.3 |
Merger & Restructuring Charges | - | - | - | - | -13 | -10.3 |
Gain (Loss) on Sale of Investments | -0.63 | -0.63 | -1.59 | -7.28 | -8.72 | 1.47 |
Asset Writedown | - | - | -0.89 | -0.68 | - | -10.66 |
Other Unusual Items | 0 | 0 | -0 | 0.05 | 0.14 | 0.75 |
Pretax Income | -348.69 | -413.65 | -583.89 | -417.29 | -349.84 | -226.03 |
Income Tax Expense | - | - | -0.04 | 0.03 | 0.01 | -1.85 |
Earnings From Continuing Operations | -348.69 | -413.65 | -583.85 | -417.32 | -349.85 | -224.19 |
Minority Interest in Earnings | 0.08 | 0.08 | 0.66 | 0.75 | 3.06 | 2.34 |
Net Income | -348.62 | -413.56 | -583.2 | -416.57 | -346.79 | -221.85 |
Net Income to Common | -348.62 | -413.56 | -583.2 | -416.57 | -346.79 | -221.85 |
Shares Outstanding (Basic) | 856 | 697 | 509 | 400 | 389 | 377 |
Shares Outstanding (Diluted) | 856 | 700 | 509 | 400 | 389 | 377 |
Shares Change (YoY) | 25.58% | 37.71% | 27.19% | 2.74% | 3.23% | 2.93% |
EPS (Basic) | -0.41 | -0.59 | -1.15 | -1.04 | -0.89 | -0.59 |
EPS (Diluted) | -0.42 | -0.62 | -1.15 | -1.04 | -0.89 | -0.59 |
Free Cash Flow | -324.76 | -398.12 | -397.34 | -415.67 | -307.98 | -173.39 |
Free Cash Flow Per Share | -0.38 | -0.57 | -0.78 | -1.04 | -0.79 | -0.46 |
Gross Margin | 99.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -315.84% | -2334.24% | -58096.95% | -146111.67% | -33985.44% | -33169.09% |
Profit Margin | -422.28% | -2804.77% | -93761.41% | -173569.58% | -37129.55% | -36669.59% |
Free Cash Flow Margin | -393.38% | -2700.06% | -63881.19% | -173196.25% | -32974.52% | -28660.00% |
EBITDA | -244.95 | -326.63 | -342.85 | -332.41 | -303.19 | -187.93 |
D&A For EBITDA | 15.8 | 17.55 | 18.51 | 18.26 | 14.24 | 12.74 |
EBIT | -260.75 | -344.18 | -361.36 | -350.67 | -317.42 | -200.67 |
Revenue as Reported | 82.56 | 14.75 | 0.62 | 0.24 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.